Progress on medication-related osteonecrosis of the jaw / 华西口腔医学杂志
West China Journal of Stomatology
; (6): 568-572, 2018.
Article
in Zh
| WPRIM
| ID: wpr-772457
Responsible library:
WPRO
ABSTRACT
Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of bisphosphonates (BPs) or other targeted agent therapies. MRONJ appears as exposed bone, pus, and swelling in the oral and maxillofacial regions. However, neither surgery nor conservative therapy can eliminate symptoms thoroughly. In addition to BPs, several antiresorptive and antiangiogenic agents, such as denosumab and bevacizumab, as well as targeted agents, such as sunitinib and temsirolimus, can cause osteonecrosis of the jaw according to the literature. This review aims to summarize the research progress on these new drugs.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Angiogenesis Inhibitors
/
Therapeutic Uses
/
Diphosphonates
/
Drug Therapy
/
Bone Density Conservation Agents
/
Bisphosphonate-Associated Osteonecrosis of the Jaw
/
Denosumab
Limits:
Humans
Language:
Zh
Journal:
West China Journal of Stomatology
Year:
2018
Type:
Article